Clinical trial NCT03881748: Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy
Official title: A Randomized Phase II Pilot Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Peripheral Neuropathy
Keywords: Acupuncture
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2019-03-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assigned to one of two groups: 1) manual acupuncture twice a week for 20 treatments or 2) electro-acupuncture twice a week for 20 treatments. Multiple assessments will be performed at baseline and approximately every 2 weeks for a total of 16 weeks while subjects are on study.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical research study is to learn if one acupuncture treatment approach is more effective than another in helping to relieve chemo-therapy induced neuropathy in cancer patients. If eligible to take part in this study, participants will be randomly assigned to 1 of 2 groups - group 1 participants will receive traditional acupuncture treatments 2 times a week for a total of 20 sessions. Group 2 participants will have acupuncture sessions with electrical stimulation 2 times a week for a total of 20 sessions.

Detailed description: Peripheral neuropathy is a common problem among cancer patients who have received chemotherapy treatment. Peripheral neuropathy often causes weakness, numbness and pain, usually in the hands and feet. It can also affect other areas of the body. People with peripheral neuropathy generally describe the pain as stabbing, burning or tingling.

Acupuncture is a technique that may treat symptoms by inserting very thin, solid, sterile, stainless steel needles into the skin at specific points. Research has shown that acupuncture can reduce symptoms of pain and nausea by altering pain signaling along nerves. The effect of acupuncture can be enhanced by additional movement of the needles called manual acupuncture, which involves rotating the needle and moving it up and down. Another type of acupuncture is called electro-acupuncture, which involves running a low level electrical current between two needle points. Preliminary studies indicate that acupuncture may also be helpful to treat chemotherapy related neuropathy. This trial will determine the relative effects of both manual acupuncture and electro-acupuncture for treating chronic chemotherapy-induced neuropathy.

Participants will be assigned to one of two groups: 1) manual acupuncture twice a week for 20 treatments or 2) electro-acupuncture twice a week for 20 treatments. Multiple assessments will be performed at baseline and approximately every 2 weeks for a total of 16 weeks while subjects are on study.

Eligibility criteria: Inclusion Criteria:

* Participants must have the ability to understand English, sign a written informed consent document, and be willing to follow protocol requirements.
* History of a diagnosis of cancer, verifiable through documentation in a medical record.
* Participants must have neuropathy ≥1 according to CTCAE v 4.0 scale or a neuropathy score of \>3 on a 0-10 scale despite previous treatment, which may include Neurontin, Cymbalta and/or Lyrica.
* The participant's previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team.
* More than 6 months since last treatment
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
* Willingness to comply with all study interventions of acupuncture and follow-up assessments.

Exclusion Criteria:

* Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period. Hormonal therapy is allowed.
* Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months.
* Local infection at or near the acupuncture site. (Although acupuncture is a minimally invasive procedure, participants will be excluded if there is an indication of infection.)
* Physical deformities that could interfere with accurate acupuncture point location.
* Concurrent use of other alternative medicines such as herbal agents and high dose vitamins and minerals.
* Known coagulopathy or taking heparin (including low molecular weight heparin) at full anti-coagulation doses (prophylaxis is allowed) or Coumadin at any dose. Participants on aspirin or non-steroidal anti-inflammatories or other antiplatelet medicines will be allowed to participate.
* Platelets \< 50 H K/UL in the past 30 days.
* White Blood Cells (WBCs) \< 3.0 K/UL or absolute neutrophil count (ANC) \<1,500 K/UL) in the past 30 days.
* Active Central Nervous System (CNS) disease. (The action for acupuncture may be associated with central nervous system activity, and participants with CNS pathology may respond differently to treatment than the general population.)
* Implanted electrical device such as cardiac pacemaker, insulin pump, or pain pump.
* Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry. (These participants may not be able to cooperate with this slightly invasive procedure or with the data collection process.)
* Currently pregnant. (Certain acupuncture applications have been reported to stimulate uterine contractions.)
* History of diabetic neuropathy, neuropathy related to HIV, or other medical causes of chronic neuropathy in the baseline assessment including past medical history, any history of diabetes, alcoholism, and vitamin B.
* Previous acupuncture treatment for any indication within 30 days of enrollment.
* Planned or actual changes in type of medications that could affect symptoms related to chemotherapy-induced peripheral neuropathy (CIPN). New medications for the treatment of CIPN are not allowed during the study. Subjects need to be on stable doses of CIPN medications for 4 weeks.
* Grade III lymphedema or lymphedema considered severe by the treating clinician

Primary outcomes:
measure: Treatment completion rate
timeFrame: Up to 12 weeks from start of study.
Secondary outcomes:
measure: Cancer-specific, health-related quality of life as measured by FACT-G
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Peripheral neuropathy or neuropathy as measured by (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity subscale (FACT/GOG-Ntx)
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Quality of life as measured by Total Neuropathy Score - Clinically Based (TNSc)
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Quality of life as measured by Neuropathy Pain Scale (NPS)
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Change in participant's ability to detect thermal sensory stimuli as measured by Quantitative Sensory Testing (QST)
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Change in participant's ability to detect vibration sensory stimuli as measured by Quantitative Sensory Testing (QST)
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Change in hand function as measured by Grooved Pegboard Test (GPT)
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Change in balance as measured by Unipedal Stance balance test
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
measure: Use of neuropathic and pain medications
timeFrame: At 2, 4, 6, 8, 10, and 14 weeks after start of treatment.
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: University Hospitals Cleveland Medical Center
name: Richard Lee, MD
role: PRINCIPAL_INVESTIGATOR
References: